Nurix advances bexobrutideg: Stifel raises target for Nurix Therapeutics stock

Published on 10/16/2026 at 01:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nurix reported USD 673.1 million revenue in the third quarter on October 12, 2026. Nurix Therapeutics stock drew a USD 41.00 Stifel target from USD 40.00.

Clinical progress and analyst response

Nurix reported USD 673.1 million in revenue for the quarter ended August 31, 2026.
The October 7, 2026 update advanced a 600 mg bexobrutideg trial with 1:1 randomization.
Stifel raised its target from USD 40.00 to USD 41.00 on October 13, 2026.

NRIX, US67080M1036, Illustration mit AI erstellt.

Nurix Therapeutics (ISIN US67080M1036) reported USD 673.1 million in revenue for its fiscal third quarter ended August 31, 2026, while advancing bexobrutideg into Phase 3 development. In its October 12, 2026 release, Nurix Therapeutics said the first patient had been dosed in the registrational DAYBreak CLL-306 trial.

Revenue rose on Roche collaboration

The revenue figure compared with USD 7.9 million in the year-earlier quarter, a USD 665.2 million increase. The company attributed USD 653.2 million to Roche license revenue and USD 10.0 million to a Sanofi development milestone, making the result heavily dependent on collaboration income rather than recurring product sales.

Net income reached USD 549.8 million, or USD 4.73 per diluted share, compared with a net loss of USD 86.4 million, or USD 1.03 per share, in the year-earlier period. Cash, cash equivalents and marketable securities totaled USD 1.1 billion as of August 31, 2026, after the Roche collaboration included a USD 700.0 million upfront payment, according to Nurix Therapeutics.

Three milestones shape the pipeline

On August 4, 2026, Nurix announced a USD 10.0 million milestone tied to the initiation of a Phase 1 STAT6 degrader trial, as shown on the company's investor-relations page. On October 7, 2026, the company reported first-patient enrollment in a Phase 1b/2 bexobrutideg combination study, according to Nurix Therapeutics. On October 12, 2026, the company reported the third-quarter results and the Phase 3 advance.

What does Phase 3 mean for the program?

DAYBreak CLL-306 compares bexobrutideg with pirtobrutinib in relapsed or refractory CLL and SLL. Patients are randomized 1:1 to receive bexobrutideg at 600 mg once daily or the comparator, with response rate and progression-free survival as the dual primary endpoints. Nurix also reported a median progression-free survival of 22.1 months and an 83.0 percent objective response rate in an earlier study.

Analyst target moves higher

Stifel raised its target for Nurix from USD 40.00 to USD 41.00 on October 13, 2026, while maintaining a Buy rating, according to Investing.com. The company had a market capitalization of USD 2.6 billion as of October 15, 2026. For investors, the central issue is whether Roche-backed clinical progress can convert collaboration-driven revenue into durable development value.